(Q35552693)

English

The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias

scientific article published on 16 April 2013

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Paul G. Richardson

7

object named as

Paul Richardson

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Kenneth C. Anderson

8

object named as

Kenneth Anderson

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

6

object named as

Jake Delmore

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Constantine S Mitsiades

10

object named as

Constantine S Mitsiades

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

2

object named as

Melissa G Ooi

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Steffen Klippel

5

object named as

Steffen Klippel

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Jana Jakubikova

4

object named as

Jana Jakubikova

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

9

object named as

Martin Clynes

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

11

object named as

Peter O'Gorman

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

author name string

Robert O'Connor

1

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Justine Meiller

3

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

16 April 2013

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

71

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

1357-1368

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

The role of tumour-stromal interactions in modifying drug response: challenges and opportunities

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4414393

12 July 2018

Microenvironmental influence on pre-clinical activity of polo-like kinase inhibition in multiple myeloma: implications for clinical translation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4414393

12 July 2018

Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4414393

12 July 2018

Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4414393

12 July 2018

Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4414393

12 July 2018

Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4414393

12 July 2018

Bortezomib restores stroma-mediated APO2L/TRAIL apoptosis resistance in multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4414393

12 July 2018

Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4414393

12 July 2018

Tyrosine kinase inhibitors potentiate the cytotoxicity of MDR-substrate anticancer agents independent of growth factor receptor status in lung cancer cell lines.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4414393

12 July 2018

The effects of proteasome inhibitor bortezomib on a P-gp positive leukemia cell line K562/A02.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4414393

12 July 2018

In vitro activity of bortezomib in cultures of patient tumour cells--potential utility in haematological malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4414393

12 July 2018

PI3K/Akt inhibition modulates multidrug resistance and activates NF-kappaB in murine lymphoma cell lines.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4414393

12 July 2018

Proteasome inhibitor MG132 reverses multidrug resistance of gastric cancer through enhancing apoptosis and inhibiting P-gp

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4414393

12 July 2018

Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4414393

12 July 2018

New drugs for myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4414393

12 July 2018

Proteomic analysis to dissect mitoxantrone resistance-associated proteins in a squamous lung carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4414393

12 July 2018

The pharmacology of cancer resistance.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4414393

12 July 2018

Activity of bortezomib in glioblastoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4414393

12 July 2018

Cell-cell contact mediated signalling - no fear of contact.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4414393

12 July 2018

Proteasome inhibitors can alter the signaling pathways and attenuate the P-glycoprotein-mediated multidrug resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4414393

12 July 2018

The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4414393

12 July 2018

Overcoming Drug Resistance in Multiple Myeloma: The Emergence of Therapeutic Approaches to Induce Apoptosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4414393

12 July 2018

NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4414393

12 July 2018

Induction of human MDR1 gene expression by 2-acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase pathway that activate NF-kappaB signaling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4414393

12 July 2018

Microplate screening of the differential effects of test agents on Hoechst 33342, rhodamine 123, and rhodamine 6G accumulation in breast cancer cells that overexpress P-glycoprotein

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4414393

12 July 2018

Induction of Mdr1b expression by tumor necrosis factor-alpha in rat liver cells is independent of p53 but requires NF-kappaB signaling.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4414393

12 July 2018

Up-regulation of multidrug resistance P-glycoprotein via nuclear factor-kappaB activation protects kidney proximal tubule cells from cadmium- and reactive oxygen species-induced apoptosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4414393

12 July 2018

Role of SR-4987 stromal cells in the modulation of doxorubicin toxicity to in vitro granulocyte-macrophage progenitors (CFU-GM).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4414393

12 July 2018

Idarubicin overcomes P-glycoprotein-related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4414393

12 July 2018

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4414393

12 July 2018

Multiple drug-resistance in variant of a human non-small cell lung carcinoma cell line, DLKP-A

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4414393

12 July 2018

Increased ABCB1 Expression in TP-110-Resistant RPMI-8226 Cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4414393

26 September 2018

The mechanism of cross-resistance to proteasome inhibitor bortezomib and overcoming resistance in Ewing's family tumor cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4414393

26 September 2018

Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4414393

26 September 2018

Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Gr

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4414393

26 September 2018

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4414393

26 September 2018

Expression of MDR1/P-glycoprotein, the multidrug resistance protein MRP, and the lung-resistance protein LRP in multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4414393

26 September 2018

Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study (06914).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4414393

26 September 2018

The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4414393

26 September 2018

P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4414393

26 September 2018

P-glycoprotein expression in primary and metastatic transitional cell carcinoma of the bladder.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4414393

26 September 2018

A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4414393

26 September 2018

Enhancement of chemotherapeutic drug toxicity to human tumour cells in vitro by a subset of non-steroidal anti-inflammatory drugs (NSAIDs)

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2136-7

21 January 2018

Transforming growth factor-beta1: differential effects on multiple myeloma versus normal B cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/23589314

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Knockdown of PgP resensitizes leukemic cells to proteasome inhibitors

1 reference

https://pubmed.ncbi.nlm.nih.gov/23589314

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study

1 reference

https://pubmed.ncbi.nlm.nih.gov/23589314

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The human multidrug resistance P-glycoprotein is inactive when its maturation is inhibited: potential for a role in cancer chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/23589314

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Characterization of marrow stromal (fibroblastoid) cells and their association with erythropoiesis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23589314

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Acid phosphatase: endpoint for in vitro toxicity tests

1 reference

https://pubmed.ncbi.nlm.nih.gov/23589314

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B

1 reference

https://pubmed.ncbi.nlm.nih.gov/23589314

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00280-013-2136-7

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35552693&oldid=2197470983"